Cybin’s Paul Glavine buys EUR 1.07m as psychedelic peers run

A sector that has stopped asking for permission

The psychedelic biotech group has spent 2026 doing something it rarely managed in earlier cycles, holding investor attention long enough to matter. The catalyst mix is obvious enough. Policy has turned less hostile, research funding has improved, and the space got a fresh credibility jolt in July when Eli Lilly agreed to acquire ataiBeckley for up to $3.8 billion, a deal that gave the market a live benchmark for what a large pharma buyer might pay for assets in this lane. That matters because the names in this pocket of biotech do not trade on current revenue. They trade on timing, probability and the market's willingness to fund the next readout.

Cybin sits inside that trade. Its lead asset, HLP003, is in a Phase 3 APPROACH trial for adjunctive major depressive disorder, with topline data expected in Q4 2026 and an NDA filing targeted for 2028. This is the sort of timeline that can keep a stock alive when the sector is hot and punish it when the market wants nearer cash flow. The shares closed at CA$12.97 on September 11, up modestly on the day, and they have already moved a long way from the 52 week low around CA$3.76. The range tells you the market is not treating this as a sleepy small cap. It is treating it as a catalyst name.

The filing and the market backdrop

Glavine, Cybin's chief growth officer, bought 100,000 common shares on September 8 at a weighted average price of $12.4719 per share, for a total filing value of about EUR 1.247 million, euro-normalised at ingest. The Form 4 was filed on September 11. His direct holdings rose to 4,271,252 shares, plus 230,941 shares held indirectly through the PLG Family Trust. That is a real purchase, not a token gesture, and it landed while the stock was already trading near the top of its recent range.

Insiders Trades data flags the buy as part of a cluster, and that is the part that deserves attention. Executive Chair Eric So also bought around the same period, and the recent declaration count in the cluster is not a one-off blip. You do not need to romanticize that. You only need to notice that multiple insiders were willing to add exposure in the same window, in a name whose next major clinical catalyst is still ahead of it. Our scoring leans on that combination, plus the fact that the filing size is about 0.14% of the company's market value. For a small or mid-cap biotech, that is not pocket change.

Why the peer set is doing the heavy lifting

Cybin does not trade in isolation. It trades against Compass Pathways, GH Research and ataiBeckley, and those comparables have changed the conversation. Compass and GH Research have both benefited from the market's appetite for clinical progress in major depressive disorder and related psychiatric indications. The ataiBeckley transaction gave the group a fresh acquisition reference point, and that matters more than usual in a sector where the exit path has often been the missing part of the story.

That peer strength has also made the market more selective. It is one thing to own the whole basket when policy headlines are supportive. It is another to decide which name deserves capital ahead of a Phase 3 readout. Cybin's answer is timing. The company has a near-term topline catalyst in Q4 2026, while the NDA target sits further out in 2028. That gives the stock a cleaner event path than many earlier-stage psychedelic names, but it also means the market will keep re-pricing it around every data whisper, every regulatory comment and every shift in risk appetite.

The sector backdrop is not just about headlines. It is about how capital rotates into names with binary upside and enough institutional credibility to survive the wait. The April 2026 presidential directive that accelerated regulatory review pathways and boosted research funding for psychedelics helped create that environment. Once that happened, the market stopped treating the space as a curiosity and started treating it as a tradable biotech sub-sector again. That is why the Lilly deal mattered. It was not just a headline. It was a valuation anchor.

Cybin's place in the trade is a catalyst, not a balance sheet story

Cybin's market cap sits at about EUR 772.3 million, which puts it squarely in the sweet spot where insider activity has historically been least priced-in, according to our dossier. That does not mean the stock is cheap. It means the market is still willing to move on new information, and insider buying can matter more here than it would in a mega-cap where every filing is already buried under a mountain of flow.

The company is not being read through a revenue lens. It is being read through a clinical lens. HLP003 in Phase 3 is the core of the setup, and the market is effectively asking whether the asset can clear the next hurdle with enough quality to justify the current valuation and the next leg higher. That is why the insider buy matters in context. A chief growth officer buying 100,000 shares at a weighted average price of $12.4719 is not proof of anything on its own, but it does tell you someone inside the company was willing to add size before the next major data point.

The stock's recent trading range also matters. A close at CA$12.97 on September 11, with a 52 week range from roughly CA$3.76 to CA$14.35, leaves the shares in a zone where good news can still matter and bad news can still hurt. That is the kind of tape that rewards patience only if the catalyst path stays intact. If the Phase 3 timeline slips, the market will not be charitable. If the data lands well, the stock has room to keep working because the market has already shown it will pay for this theme.

The insider cluster and the cohort data

The cluster is real. Insiders Trades data shows four distinct insiders in the recent window and 12 recent declarations tied to the name. Glavine's buy sits alongside purchases by Executive Chair Eric So, and the pattern is consistent with a board and management group that is not hiding from the stock at current levels. That is the useful read. It is a cluster of open-market buying in a company with a live Phase 3 catalyst, not a single director nibbling for optics.

Our cohort data gives the historical frame. In the bucket of director-level buys at sweet-spot names between EUR 300 million and EUR 1 billion, the sample shows a 53% 90-day win rate, a 90-day average return of 3.97%, and a 365-day average return of 82.12%. That is historical cohort data for a role-and-size bucket, not a forecast for Cybin and not a promise that this filing will work. The point is narrower. In this part of the market, insider buying has tended to show up in names that can still re-rate when the next catalyst lands.

The strategy token belongs in the same frame, with the caveat attached. Our point-in-time backtest headline sits at 0.68, 9.9% (STOXX Europe 600 on the same dates: 8.0%) and (figure withdrawn, see audit 231) on the restricted EU venue universe, and those figures survive only in that narrow regime. They are useful as a screen, not as a promise. The market changes, the regime changes, and a single Sharpe number does not travel well outside the window that produced it.

The risk case for Cybin

Cybin's biggest risk is not that the stock is expensive in some abstract sense. It is that the market is paying for a clinical path that still has to clear the next major test. Q4 2026 topline data is the obvious checkpoint. If that readout disappoints, the current insider buying will not protect the shares from a reset. If the data is strong, the market will probably focus on the NDA path and the possibility that the company can keep its place in the front rank of psychedelic biotech names.

There is also the usual biotech problem of timing. A stock can be right on the science and wrong on the calendar. That is especially true in a sector where policy support can improve sentiment faster than it improves execution. The Lilly deal and the April directive have helped the group, but they do not remove trial risk. They only make the market more willing to pay for the next step.

The peer set keeps that tension visible. Compass Pathways and GH Research have shown that the market will reward progress, but it has also shown that it will not pay the same multiple for every name in the space. Cybin has to earn its place with data. The insider cluster helps the stock's case because it shows management is willing to buy into that calendar. It does not change the calendar itself.

Where the filing lands now

The cleanest company-specific read is that Glavine bought size into strength, not weakness. A 100,000 share purchase at a weighted average price of $12.4719, for about EUR 1.247 million, is a meaningful addition for an executive already holding more than 4.27 million direct shares. Add the indirect trust stake and the position is larger still. That is the sort of filing you expect to see when insiders think the next catalyst matters more than the recent run.

The market will decide whether that matters. For now, the stock is still trading in a sector that has regained momentum, and Cybin has a live Phase 3 event in Q4 2026 while peers continue to set the tone for valuation and sentiment. The insider cluster gives you a reason to keep the name on the screen. The sector backdrop gives you a reason to understand why the market is paying attention. The next hard fact is the topline data window, and that is where this story will either get easier or get much harder.

Dig deeper: Cybin Inc.'s full insider filing history and Glavine Paul's filing track record.

This is not investment advice.